

Short communication

Does prearrest adrenergic integrity affect pressor response? A comparison of epinephrine and vasopressin in a spontaneous ventricular fibrillation swine model^{☆,☆☆}

Scott T. Youngquist^{a,b,*}, Atman Shah^c, Christian McClung^d, Joseph L. Thomas^e, John P. Rosborough^f, James T. Niemann^f

^a Department of Surgery, Division of Emergency Medicine, United States

^b Air Medical Research Institute, University of Utah School of Medicine, Salt Lake City, UT, United States

^c Department of Medicine, the Division of Cardiology, the University of Chicago, Chicago, IL, United States

^d Department of Emergency Medicine, the Los Angeles County-University of Southern California Medical Center, Los Angeles, CA, United States

^e Department of Medicine, the Division of Cardiology, Harbor-UCLA Medical Center, Torrance, CA, United States

^f Department of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, CA, United States

ARTICLE INFO

Article history:

Received 6 May 2010

Received in revised form

18 September 2010

Accepted 4 October 2010

Keywords:

Cardiac arrest

Cardiopulmonary resuscitation

Beta-blockers

Coronary perfusion pressure

ABSTRACT

Objectives: Coronary perfusion pressure (CPP) during resuscitation from cardiac arrest has been shown to correlate with return of spontaneous circulation. Adrenergic blockade of beta-1 and alpha-1 receptors is common in the long-term management of ischemic heart disease and congestive heart failure. We sought to compare the CPP response to vasopressin vs. epinephrine in a swine model of cardiac arrest following pre-arrest adrenergic blockade.

Methods: Eight anesthetized and instrumented swine were administered 0.1 mg epinephrine and arterial pressure and heart rate response were measured. An infusion of labetalol was then initiated and animals periodically challenged with epinephrine until adrenergic blockade was confirmed. The left anterior descending coronary artery was occluded to produce ventricular fibrillation (VF). After 7 min of untreated VF, mechanical chest compressions were initiated. After 1 min of compressions, 1 mg epinephrine was given while CPP was recorded. When CPP values had returned to pre-epinephrine levels, 40 U of bolus vasopressin was given. Differences in CPP (post-vasopressor–pre-vasopressor) were compared within animals for the epinephrine and vasopressin response and with eight, non-adrenergically blocked, historical controls using Bayesian statistics with a non-informative prior.

Results: The CPP response following epinephrine was 15.1 mmHg lower in adrenergically blocked animals compared to non-adrenergically blocked animals (95% Highest Posterior Density [HPD] 2.9–27.2 mmHg lower). CPP went up 18.4 mmHg more following vasopressin when compared to epinephrine (95% HPD 8.2–29.1 mmHg). The posterior probability of a higher CPP response from vasopressin (vs. epinephrine) in these animals was 0.999.

Conclusions: Pre-arrest adrenergic blockade blunts the CPP response to epinephrine. Superior augmentation of CPP is attained with vasopressin under these conditions.

© 2010 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Current advanced cardiac life support (ACLS) guidelines recommend the administration of a vasopressor medication, either epinephrine or vasopressin, during cardiac arrest due to PEA or asystole or if ventricular fibrillation (VF) or pulseless ventricular tachycardia persist after one or two shocks with CPR.¹ The rationale for this approach is to pharmacologically augment coronary perfusion pressure (CPP), the pressure gradient between aortic and right atrial pressures during the relaxation phase of rhythmic chest compressions. Higher CPP has been correlated with improved return of spontaneous circulation (ROSC) in animals and humans.^{2–4} Despite strong rationale supported by hemodynamic

[☆] A Spanish translated version of the abstract of this article appears as Appendix in the final online version at doi:10.1016/j.resuscitation.2010.10.004.

^{☆☆} This study was supported, in part, by a grant from the National Institutes of Health, NHLBI R01 HL076671.

* Corresponding author at: University of Utah, Division of Emergency Medicine, 30 North 1900 East, Room 1C026, Salt Lake City, UT 84132, United States. Tel.: +1 801 581 2730.

E-mail addresses: youngquist@hotmail.com, scott.youngquist@utah.edu (S.T. Youngquist).

observations in animal models, vasopressors have not been shown to improve outcome in observational reports or clinical trials.^{5–7}

Medications used by patients prior to cardiopulmonary collapse may affect the response to pharmacologic therapy administered during resuscitation efforts. No consideration is currently included in ACLS guidelines regarding the use of chronic medications prior to arrest, particularly those that might affect hemodynamic variables during CPR. Approximately 80% of post-infarction patients are prescribed a beta blocker at discharge.⁸ Carvedilol, classified as a non-selective beta blocker, is more commonly prescribed than selective beta-1 antagonists, including metoprolol succinate, for the management of heart failure.⁹

The purpose of this investigation was to compare the effect of epinephrine with that of vasopressin on coronary perfusion pressure in a porcine model of ischemic VF cardiac arrest when preceded by blockade of alpha-1 and beta-1 adrenergic receptors.

2. Methods

This study was approved by the Animal Care and Utilization Review Committee at our institution and conforms to the American Physiological Society's Guiding Principles in the Care and Use of Animals.

Methods for the induction of anesthesia and instrumentation have been previously described.¹⁰ In brief, 8 male mixed breed Yorkshire swine (41 ± 3 kg) were premedicated with ketamine and xylazine and anesthesia was induced and maintained with inhaled isoflurane. End-tidal CO₂ was monitored continuously and minute ventilation was adjusted to maintain an end-tidal CO₂ between 35 and 45 mmHg. Lead II of the surface electrocardiogram was also monitored continuously throughout the protocol.

Vessels were exposed surgically and high-fidelity micro-manometer tipped catheters (Millar Instruments, Houston, TX) were positioned in the ascending aorta (Ao) and the right atrium (RA) under fluoroscopic guidance. Following instrumentation, heart rate, systolic and diastolic aortic and mean RA pressures were measured and recorded (PowerLab Chart acquisition software v. 5.2, ADInstruments, Castle Hill, Australia). Arterial blood gas was analyzed (I-Stat EG7+, I-Stat Corp, Princeton, NJ) at baseline following instrumentation and at intervals throughout the investigation.

After control measurements were made, a 0.1 mg bolus of epinephrine was administered via the RA catheter and the heart rate and arterial pressure response recorded. After heart rate and arterial pressure returned to baseline values, an intravenous infusion of labetalol was begun and continued until an additional epinephrine challenge produced a <10 beat/min change in heart rate and systolic arterial pressure increased by <25%, a definition based on the consensus agreement of the investigators. (Carvedilol is currently unavailable in a titratable intravenous formulation, which is why labetalol was chosen as comparable mixed agonist.)

After adrenergic blockade, the left anterior descending (LAD) coronary artery distal to the first septal perforator was occluded with a standard angioplasty catheter and balloon (Voyager 4.0 mm × 20 mm PTCA balloon, Abbott Vascular, Temecula CA). The site of coronary occlusion and confirmation of complete cessation of coronary flow distal to the balloon were confirmed with manual contrast injections. Animals were observed until spontaneous VF occurred.

Following 7 min of untreated VF, closed mechanical chest compressions with the Thumper[®] (Michigan Instruments, Grand Rapids, MI) were initiated with force sufficient to depress the sternum 1.5–2.0 in. Following 1 min of closed chest compressions, epinephrine 1 mg was administered via the RA during continuous recording of CPP. When the CPP had returned to pre-epinephrine baseline, vasopressin, 40 U, was delivered via the RA catheter. The

order of administration was chosen due to the relatively short half-life of epinephrine (approximately 5 min) and the relatively long half-life (approximately 20 min) of vasopressin in an attempt to minimize carryover effects and temporal declines in vascular responsiveness. Each animal served as their own control to reduce the potential effect of genetic and physiologic variability on the differential response.

An identical protocol, omitting pre-arrest adrenergic blockade or epinephrine challenge, was performed in eight additional swine who served as non-adrenergically blocked controls.

2.1. Data analysis

Data were entered into an Excel Spreadsheet (v. 12.0, Microsoft Corp, Redmond, WA) and imported into SAS statistical software (v. 9.2, SAS Institute, Cary, NC) for analysis. CPR coronary perfusion pressure (diastolic or relaxation phase Ao-RA pressure difference) was determined by measuring the mean peak CPP over the 30 s period (approximately 50 compression cycles) preceding medication administration (epinephrine or vasopressin) and the 30 s period following medication administration.

Differences in CPP response to epinephrine (post-epinephrine CPP–pre-epinephrine CPP) between adrenergically blocked and non-adrenergically blocked animals and the differences in CPP response to vasopressin vs. epinephrine within blocked animals were modeled using Bayesian statistics. Utilizing Markov-Chain Monte Carlo random sampling methods, the Bayesian model allows for the assignment of exact probability values to specific hypotheses, rather than simply the null hypothesis. Specifically, the Bayes option of the SAS procedure, PROC GENMOD, was invoked for this purpose. We used non-informative, uniform prior distributions (assigning equal probability to all values), to model uncertainty regarding the location of the parameter μ , the difference in mean CPP response. A default, non-informative gamma prior probability distribution was used to model uncertainty in the scale parameter (σ) of the target distribution. Markov chain convergence was assessed using visual inspection of trace plots and three standard diagnostics: Lag autocorrelations, Geweke diagnostic statistics, and effective sample sizes. We report median values and 95% highest posterior density (HPD) intervals for the posterior probability distributions. These intervals reflect the parameter values which are assigned 95% of the posterior probability.

3. Results

An average of 7 ± 2 mg/kg of labetalol was required to produce blockade of alpha 1 and beta-1 receptors. Fig. 1 demonstrates the change in CPP following administration of either epinephrine or vasopressin to adrenergically blocked animals when compared to pharmacologically naïve (non-adrenergically blocked) animals.

Markov chain convergence was satisfactory for all posterior sampling densities. Table 1 provides results of posterior

Table 1
Posterior probability estimates for the coronary perfusion pressure response following vasopressor administration in a swine model of cardiac arrest.

Vasopressor	Mean Δ CPP (mmHg)	95% HPD ^a (mmHg)
Non-blocked ($n = 8$)		
Epinephrine	24.6	15.9–32.8
Non-selective blockade ($n = 8$)		
Epinephrine	9.5	5.6–12.9
Vasopressin	27.9	16.8–39.6

^a Highest posterior density: the range of parameter values assigned the 95% highest posterior probability.




Fig. 1. Dot plots for the increase in coronary perfusion pressure (CPP) during cardiac arrest with mechanical chest compressions following the administration of vasopressor medication to two cohorts: (1) pharmacologically naïve swine administered epinephrine, and (2) swine that underwent pre-arrest non-selective adrenergic blockade and were administered first epinephrine during resuscitation and then xx minutes later, when CPP levels had returned to baseline, vasopressin.

probability distributions for the CPP response following vasopressor administration. Adrenergically blocked animals showed a CPP response that was 15.1 mmHg lower than that observed in non-adrenergically blocked animals (median 15.1, 95% HPD 2.9–27.2 mmHg lower). The posterior probability of a higher CPP response following epinephrine in adrenergically blocked animals (vs. non-adrenergically blocked animals) was only 0.008. On the other hand, the posterior probability of at least a –10 mmHg or lower CPP response in adrenergically blocked animals was 0.81. The posterior probability of at least a –20 mmHg or lower CPP response in adrenergically blocked animals was 0.20.

In adrenergically blocked animals, the CPP response was, on average, 18.4 mmHg higher following vasopressin administration when compared to epinephrine (median 18.4, 95% HPD 8.2–29.1 mmHg). The posterior probability of a higher CPP response from vasopressin (vs. epinephrine) in adrenergically blocked animals was 0.999. The posterior probability of at least a 10 mmHg higher CPP response following vasopressin was 0.94. The posterior probability of at least a 20 mmHg higher CPP response following vasopressin was 0.37.

4. Discussion

It is likely that patients at greatest risk for out-of-hospital cardiac arrest, namely those with severe left ventricular systolic dysfunction or coronary artery disease, will be receiving treatment with an adrenergic blocking agent, either a selective beta-1 blocker, e.g., metoprolol, or a drug with nonselective properties, such as carvedilol. The present investigation demonstrates that, in this porcine model of ischemic ventricular fibrillation, prior adrenergic blockade with labetalol, a mixed alpha and beta antagonist similar to carvedilol, attenuates the CPP response to epinephrine. This investigation also demonstrates that vasopressin provides superior augmentation of CPP when compared to epinephrine under these conditions. Epinephrine increased CPP to >20 mmHg in only one animal. This CPP value has been demonstrated to reliably predict successful defibrillation and ROSC in the swine electrically induced VF cardiac arrest model.⁴

Several clinical reports have questioned the utility of drug administration during advanced cardiac life support.^{5–7} Additionally, the benefits of vasopressin administration, alone or when combined with epinephrine, in clinical cardiac arrest have yielded equivocal results.¹¹ However, these clinical trials have not included chronic adrenergic blocker therapy as a pre-arrest variable during the course of data and outcome analysis. The findings of our laboratory study suggest the existence of pre-arrest adrenergic blockade should be considered when cardiac arrest therapy trials are designed. In this study, we evaluated only the effects of pre-arrest non-selective adrenergic blockade with labetalol. This drug was selected because it has adrenergic blocker properties nearly identical to carvedilol with the exception of less β -1 potency and can be easily titrated to achieve adrenergic blockade.¹² Although myocardial β -adrenergic density is approximately the same in humans and swine,^{13,14} we assessed the adequacy of β - and α -adrenergic blockade with epinephrine challenge before and after the labetalol infusion and before coronary occlusion.

A number of laboratory studies have evaluated the effects of β -blockers in the treatment of cardiac arrest.^{15–18} These studies generally indicate that esmolol or propranolol improve myocardial function after resuscitation. However, in a number of these studies, epinephrine was not administered during resuscitation efforts or was given before β -blockade, or epinephrine's α -adrenergic effects were enhanced by β ₂-blockade. In none was adequacy of adrenergic blockade confirmed during the course of experiments. Receptor density is likely to vary between canines, swine, and murine models. We did not evaluate the effect of nonselective blockade on post-resuscitation ventricular function and whether nonselective adrenergic blockade is beneficial after resuscitation remains unknown.

This study has several limitations: (1) We pretreated only with labetalol, an agent with properties similar to carvedilol, and titration of IV adrenergic blockade, while standardized between animals, was not based on any previously published protocol. (2) Pretreatment with a selective β ₁-blocker or a combined β ₁ and β ₂ antagonist may not have yielded similar results. Pre-arrest treatment with propranolol at a dose of 2 mg/kg in an electrically induced VF canine cardiac arrest model has been shown to result in a greater increase in coronary perfusion pressure after epinephrine when compared to no pretreatment, presumably due to unopposed alpha-adrenergic stimulation of resistance vessels.¹⁸ Co-administration of a selective β ₁ antagonist (esmolol or atenolol) with epinephrine during resuscitation may increase coronary perfusion pressure when compared to epinephrine alone via an undefined mechanism.^{17,18} (3) Animals were not randomized to the order of treatment intervention due to the markedly different half lives of the two study drugs. All animals received epinephrine first and then vasopressin. Thus, the possibility for carryover effects exists. This is unlikely, however, as the effects of epinephrine are short-lived. Additionally, the pre-arrest use of epinephrine early decreased the likelihood that such use would attenuate the hemodynamic effect of a single post-arrest dose.¹⁹ (4) We did not assess the effects of nonselective blockade on post-resuscitation ventricular function. If animals could be resuscitated after epinephrine therapy alone, published studies suggest that β ₁-blockade as achieved in our study could be beneficial.

Our study indicates that pre-arrest adrenergic blockade of beta-1 and alpha-1 receptors, a combination likely to be encountered in clinical practice, can attenuate the hemodynamic effects of epinephrine during resuscitation and that vasopressin may be the preferred vasopressor. Additionally, pre-arrest adrenergic blockade should be considered when comparing outcomes of treatments in the clinical cardiac arrest population. Our findings may not apply in the setting of only selective beta-1 receptor antagonism.

Conflict of interest statement

None to declare.

References

- American Heart Association. Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7.2: Management of Cardiac Arrest. *Circulation* 2005;112:IV-58–66.
- Paradis NA, Martin GB, Rivers EP, et al. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. *JAMA* 1990;263:1106–13.
- Kern KB, Ewy GA, Voorhees WD, Babbs CF, Tacker WA. Myocardial perfusion pressure: a predictor of 24-hour survival during prolonged cardiac arrest in dogs. *Resuscitation* 1988;16:241–50.
- Reynolds JC, Salcido DD, Menegazzi JJ. Coronary perfusion pressure and return of spontaneous circulation after prolonged cardiac arrest. *Prehosp Emerg Care* 2010;14:78–84.
- van Walraven C, Stiell IG, Wells GA, Hebert PC, Vandemheen K, for the OTAC Study Group. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? *Ann Emerg Med* 1998;32:544–53.
- Ong ME, Tan EH, Ng FS, et al. Survival outcomes with the introduction of intravenous epinephrine in the management of out-of-hospital cardiac arrest. *Ann Emerg Med* 2007;50:635–42.
- Olasveengen TM, Sunde K, Brunborg C, Thowsen PA, Wik L. Intravenous drug administration during out-of-hospital cardiac arrest. *JAMA* 2009;302:2222–9.
- Pedone C, Di Pasquale G, Greco C, et al. Prescription at discharge of recommended treatments for secondary prevention in patients with ST-segment elevation myocardial infarction according to reperfusion strategies. Results from the IN-ACS outcome study. *Acute Card Care* 2009;11:222–8.
- Fonarow GC, Abraham WT, Albert NM, et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure). *Am J Cardiol* 2008;102:1524–9.
- Niemann JT, Rosborough J, Youngquist S, Thomas J, Lewis R. Is all ventricular fibrillation the same? A comparison of ischemically induced and electrically induced ventricular fibrillation in a porcine cardiac arrest and resuscitation model. *Crit Care Med* 2007;35:1356–61.
- Sillberg VAH, Perry JJ, Stiell IG, Wells GA. Is the combination of vasopressin and epinephrine superior to repeated doses of epinephrine alone in the treatment of cardiac arrest—a systematic review. *Resuscitation* 2008;79:380–6.
- Reiter MJ. Cardiovascular drug class specificity: β -blockers. *Prog Cardiovasc Dis* 2004;47:11–33.
- Delforge J, Mesangeau D, Dolle F, et al. In vivo quantification and parametric images of the cardiac β -adrenergic receptor density. *J Nucl Med* 2002;43:215–26.
- Salinas C, Muzic RF, Ernsberger P, Saidel GM. Robust experimental design for estimating myocardial β adrenergic receptor concentration using PET. *Med Phys* 2007;34:151–65.
- Bourque D, Daoust R, Huard V, Charneau M. β -blockers for the treatment of cardiac arrest from ventricular fibrillation. *Resuscitation* 2007;75:434–44.
- Ditchey RV, Rubio-Perez A, Slinker BK. Beta-adrenergic blockade reduces myocardial injury during experimental cardiopulmonary resuscitation. *J Am Coll Cardiol* 1994;24:804–12.
- Bassiakou E, Xanthos T, Koudouna E, et al. Atenolol in combination with epinephrine improves the initial outcome of cardiopulmonary resuscitation in a swine model of ventricular fibrillation. *Am J Emerg Med* 2008;26:578–84.
- Teochari E, Xanthos T, Papadimitriou D, et al. Selective beta blockade improves the outcome of cardiopulmonary resuscitation in a swine model of cardiac arrest. *Ann Ital Chir* 2008;79:409–14.
- Cairns CB, Niemann JT. Hemodynamic effects of repeated doses of epinephrine after prolonged cardiac arrest and CPR: preliminary observations in an animal model. *Resuscitation* 1998;36:181–3.